DCP Capital invests over $283m in Shanghai-listed insulin maker

DCP Capital invests over $283m in Shanghai-listed insulin maker

Insulin Level Test Conducted by an EMT. Source: Matt Chesin/Unsplash

Asia-focused private equity firm DCP Capital has reached an agreement to spend about 1.94 billion yuan (over $283 million) for a 9 per cent stake in Tonghua Dongbao Pharmaceutical, a Shanghai-listed provider of insulin used in the treatment of diabetes.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter